Octreotide is a pituitary hormone release inhibitor. Because octreotide inhibits the release of growth hormone, insulin, and glucagon, it may cause disturbances in blood glucose regulation. Because octreotide decreases postprandial glucose tolerance, persistent hyperglycemia may occur in a small number of patients who are chronically administered octreotide, and hypoglycemia has been observed, resulting in the development of abnormal blood glucose. Octreotide is commonly used in the treatment of esophago-gastric variceal bleeding due to cirrhosis and in the treatment of postoperative pancreatic complications, and may be used in combination with specific treatments such as endoscopic sclerotherapy. Octreotide is contraindicated in people who are allergic to Octreotide. Needling or burning sensation at the injection site, pain as well as gastrointestinal adverse reactions such as nausea and vomiting may occur after the use of the drug, and prolonged use may also cause gallstones and so on. Patients who need to use Octreotide should use the drug under the guidance of a doctor, and it is recommended to go to the hospital for medical treatment if there is any blood sugar abnormality after using the drug.